[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"node-by-slug-\u002Fde\u002Finsights\u002Fhealios-das-leben-der-patienten-erleichtern-durch-digitale-biomarker-de":3,"related-content-view-3339-de":367},["Reactive",4],{"entity":5,"errors":-1},{"__typename":6,"status":7,"metatag":8,"id":206,"path":207,"hideNavigation":208,"title":209,"translations":210,"sharedHeaderRefMedia":218,"sharedTeaserTitle":209,"sharedTeaserText":242,"sharedTeaserRefMedia":244,"sharedParagraphs":246,"sharedTaxrefIndustries":343,"sharedTaxrefExpertises":350,"sharedIntroText":208,"sharedCtaLink":208,"sharedDate":354,"sharedAuthor":356},"NodeInsight",true,[9,14,18,21,25,30,34,38,42,46,50,54,58,62,66,69,73,76,79,81,84,87,91,95,99,103,107,111,115,119,123,127,131,135,139,142,145,148,151,154,157,160,163,166,170,174,177,181,185,189,193,197,200,204],{"tag":10,"attributes":11},"meta",{"name":12,"content":13},"title","Healios: Mehrwert für Patienten mit digitalen Biomarkern",{"tag":10,"attributes":15},{"name":16,"content":17},"description","Interview mit Guilhem Dupont, CEO von Healios, dem jüngsten Portfolio-Unternehmen von Zühlke Ventures. Healios entwickelt digitale Biomarker, um einerseits Multiple-Sklerose-Patienten das Leben zu erleichtern und andererseits die Forschung in diesem Bereich vorwärtszubringen.",{"tag":10,"attributes":19},{"name":20,"content":17},"abstract",{"tag":10,"attributes":22},{"name":23,"content":24},"icbm","51.525772, -0.082716",{"tag":26,"attributes":27},"link",{"rel":28,"href":29},"shortlink","https:\u002F\u002Fcms.zuehlke.com\u002Fapi\u002Fgraphql",{"tag":26,"attributes":31},{"rel":32,"href":33},"canonical","https:\u002F\u002Fcms.zuehlke.com\u002Fde\u002Finsights\u002Fhealios-das-leben-der-patienten-erleichtern-durch-digitale-biomarker",{"tag":10,"attributes":35},{"name":36,"content":37},"robots","index, follow",{"tag":26,"attributes":39},{"rel":40,"href":41},"image_src","https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Fmax_1300x1300\u002Fpublic\u002Fimages\u002Fdigital_patient.png?itok=kmX1Luaf,https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fimages\u002Fzuhlke_innovation_social.jpg",{"tag":10,"attributes":43},{"name":44,"content":45},"referrer","unsafe-url",{"tag":10,"attributes":47},{"name":48,"content":49},"rights","Copyright ©2026 | Zühlke Engineering AG | All rights reserved.",{"tag":10,"attributes":51},{"property":52,"content":53},"og:site_name","Zühlke Engineering AG",{"tag":10,"attributes":55},{"property":56,"content":57},"og:type","website",{"tag":10,"attributes":59},{"property":60,"content":61},"og:url","https:\u002F\u002Fwww.zuehlke.com\u002Fde\u002Finsights\u002Fhealios-das-leben-der-patienten-erleichtern-durch-digitale-biomarker",{"tag":10,"attributes":63},{"property":64,"content":65},"og:title","Healios: das Leben der Patienten erleichtern – durch digitale Biomarker – Zühlke",{"tag":10,"attributes":67},{"property":68,"content":17},"og:description",{"tag":10,"attributes":70},{"property":71,"content":72},"og:image","https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Fmax_1300x1300\u002Fpublic\u002Fimages\u002Fdigital_patient.png?itok=kmX1Luaf",{"tag":10,"attributes":74},{"property":71,"content":75},"https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fimages\u002Fzuhlke_innovation_social.jpg",{"tag":10,"attributes":77},{"property":78,"content":72},"og:image:url",{"tag":10,"attributes":80},{"property":78,"content":75},{"tag":10,"attributes":82},{"property":83,"content":72},"og:image:secure_url",{"tag":10,"attributes":85},{"property":83,"content":86},"https:\u002F\u002Fwww.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fimages\u002Fzuhlke_innovation_social.jpg",{"tag":10,"attributes":88},{"property":89,"content":90},"og:updated_time","2025-12-29",{"tag":10,"attributes":92},{"property":93,"content":94},"og:image:alt","| Zühlke image",{"tag":10,"attributes":96},{"property":97,"content":98},"place:location:latitude","46.947944",{"tag":10,"attributes":100},{"property":101,"content":102},"place:location:longitude","7.438014",{"tag":10,"attributes":104},{"property":105,"content":106},"og:street_address","80 Great Eastern Street",{"tag":10,"attributes":108},{"property":109,"content":110},"og:locality","London",{"tag":10,"attributes":112},{"property":113,"content":114},"og:region","England",{"tag":10,"attributes":116},{"property":117,"content":118},"og:postal_code","EC2A 3JL",{"tag":10,"attributes":120},{"property":121,"content":122},"og:country_name","United Kingdom",{"tag":10,"attributes":124},{"property":125,"content":126},"og:email","london@zuhlke.com",{"tag":10,"attributes":128},{"property":129,"content":130},"og:phone_number","+44 20 7113 5000",{"tag":10,"attributes":132},{"property":133,"content":134},"og:locale","en_CH",{"tag":10,"attributes":136},{"property":137,"content":138},"og:locale:alternate","de_CH",{"tag":10,"attributes":140},{"property":137,"content":141},"de_DE",{"tag":10,"attributes":143},{"property":137,"content":144},"en_DE",{"tag":10,"attributes":146},{"property":137,"content":147},"en_AT",{"tag":10,"attributes":149},{"property":137,"content":150},"de_AT",{"tag":10,"attributes":152},{"property":137,"content":153},"en_HK",{"tag":10,"attributes":155},{"property":137,"content":156},"en_SR",{"tag":10,"attributes":158},{"property":137,"content":159},"en_BG",{"tag":10,"attributes":161},{"property":137,"content":162},"en_SG",{"tag":10,"attributes":164},{"property":137,"content":165},"en_GB",{"tag":10,"attributes":167},{"property":168,"content":169},"article:publisher","https:\u002F\u002Fwww.facebook.com\u002Fzuehlke.group",{"tag":10,"attributes":171},{"property":172,"content":173},"article:published_time","2021-03-31",{"tag":10,"attributes":175},{"property":176,"content":90},"article:modified_time",{"tag":10,"attributes":178},{"name":179,"content":180},"twitter:card","summary_large_image",{"tag":10,"attributes":182},{"name":183,"content":184},"twitter:site","@zuehlke_group",{"tag":10,"attributes":186},{"name":187,"content":188},"twitter:title","| Zühlke",{"tag":10,"attributes":190},{"name":191,"content":192},"twitter:site:id","247189965",{"tag":10,"attributes":194},{"name":195,"content":196},"twitter:image","https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Fmax_1300x1300\u002Fpublic\u002Fimages\u002Fdigital_patient.png?itok=kmX1Luaf,https:\u002F\u002Fwww.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fimages\u002Fzuhlke_innovation_social.jpg",{"tag":10,"attributes":198},{"name":199,"content":94},"twitter:image:alt",{"tag":10,"attributes":201},{"name":202,"content":203},"google-site-verification","VEzolc1Vxy1KyRIlIqUSmVS7fqP_3_ZeBqPRby4g2mE",{"tag":205},"script","3339","\u002Fde\u002Finsights\u002Fhealios-das-leben-der-patienten-erleichtern-durch-digitale-biomarker",null,"Healios: das Leben der Patienten erleichtern – durch digitale Biomarker",[211,215],{"path":212,"langcode":213},"\u002Fen\u002Finsights\u002Fhealios-improved-patient-journey-through-digital-biomarkers",{"id":214},"en",{"path":207,"langcode":216},{"id":217},"de",{"id":219,"sharedMediaLegend":208,"mediaImage":220,"name":241},"2542",{"url":221,"width":222,"height":223,"alt":224,"title":208,"size":225,"mime":226,"variations":208,"headerMinimalVariations":227},"https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fimages\u002Fdigital_patient.png",702,576,"healthcare professional analyzing data with tablet and PC",530272,"image\u002Fpng",[228,232,233,237,240],{"name":229,"url":230,"width":222,"height":231},"FOCAL_POINT32_SMALL","https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Ffocal_point_3_2_small\u002Fpublic\u002Fimages\u002Fdigital_patient.png.webp?itok=oyrzleIO",468,{"name":229,"url":230,"width":222,"height":231},{"name":234,"url":235,"width":222,"height":236},"FOCAL_POINT169_MEDIUM","https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Ffocal_point_16_9_medium\u002Fpublic\u002Fimages\u002Fdigital_patient.png.webp?itok=NFzcjH4F",395,{"name":238,"url":239,"width":222,"height":236},"FOCAL_POINT169_LARGE","https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Ffocal_point_16_9_large\u002Fpublic\u002Fimages\u002Fdigital_patient.png.webp?itok=mq3UYeeH",{"name":238,"url":239,"width":222,"height":236},"digital_patient.png",{"processed":243},"\u003Cp>Interview mit Guilhem Dupont, CEO von Healios, dem jüngsten Portfolio-Unternehmen von Zühlke Ventures. Healios entwickelt digitale Biomarker, um einerseits Multiple-Sklerose-Patienten das Leben zu erleichtern und andererseits die Forschung in diesem Bereich vorwärtszubringen.\u003C\u002Fp>",{"id":219,"sharedMediaLegend":208,"mediaImage":245,"name":241},{"url":221,"width":222,"height":223,"alt":224,"title":208,"size":225,"mime":226,"variations":208},[247,254,259,264,269,295,300,305,310],{"__typename":248,"id":249,"ctaLink":208,"pgSharedText":250,"pgSharedTitle":208,"pgSharedCtaLink":208},"ParagraphPgText","23422",{"value":251,"processed":252,"format":253},"\u003Cul>\r\n\t\u003Cli>Healios entwickelt digitale Biomarker, um das Leben der Patienten mit Multipler Sklerose zu erleichtern\u003C\u002Fli>\r\n\t\u003Cli>Dies bringt auch die Forschung in diesem Bereich weiter\u003C\u002Fli>\r\n\t\u003Cli>Das Gesundheitswesen bietet enorme Chancen in der Ära der digitalen Transformation\u003C\u002Fli>\r\n\u003C\u002Ful>\r\n","\u003Cul>\n\t\u003Cli>Healios entwickelt digitale Biomarker, um das Leben der Patienten mit Multipler Sklerose zu erleichtern\u003C\u002Fli>\n\t\u003Cli>Dies bringt auch die Forschung in diesem Bereich weiter\u003C\u002Fli>\n\t\u003Cli>Das Gesundheitswesen bietet enorme Chancen in der Ära der digitalen Transformation\u003C\u002Fli>\n\u003C\u002Ful>","full_html",{"__typename":248,"id":255,"ctaLink":208,"pgSharedText":256,"pgSharedTitle":208,"pgSharedCtaLink":208},"10414",{"value":257,"processed":258,"format":208},"Healios entwickelt digitale Biomarker, um einerseits Multiple-Sklerose-Patienten das Leben zu erleichtern und andererseits die Forschung in diesem Bereich vorwärtszubringen. Interview mit Guilhem Dupont, CEO von Healios, dem jüngsten Portfolio-Unternehmen von Zühlke Ventures.","\u003Cp>Healios entwickelt digitale Biomarker, um einerseits Multiple-Sklerose-Patienten das Leben zu erleichtern und andererseits die Forschung in diesem Bereich vorwärtszubringen. Interview mit Guilhem Dupont, CEO von Healios, dem jüngsten Portfolio-Unternehmen von Zühlke Ventures.\u003C\u002Fp>\n",{"__typename":248,"id":260,"ctaLink":208,"pgSharedText":261,"pgSharedTitle":208,"pgSharedCtaLink":208},"5659",{"value":262,"processed":263,"format":253},"\u003Cp>\u003Cem>\u003Cstrong>Guilhem, warum haben Sie eine attraktive Position in einem Grosskonzern verlassen, um Healios zu gründen?\u003C\u002Fstrong>\u003C\u002Fem>\u003Cbr \u002F>\r\n\u003Cbr \u002F>\r\nIm heutigen Zeitalter der digitalen Transformation bieten sich im Gesundheitswesen riesige Chancen. Es werden noch mehr belastbare Real-World-Daten benötigt, um den Behandlungserfolg zu messen, und wir brauchen genauere Diagnostika, mit denen sich die Behandlungen personalisieren lassen. Hier kommt Healios ins Spiel: Wir nutzen Sensordaten von Wearables und Smartphones, um das Fortschreiten neurologischer Krankheiten wie der Multiplen Sklerose (MS) zu messen. \u003Cspan style=\"font-size:11pt\">\u003Cspan style=\"vertical-align:middle\">\u003Cspan style=\"font-family:Calibri,sans-serif\">\u003Cspan lang=\"EN-GB\" style=\"font-size:12.0pt\">\u003Cspan style=\"font-family:"Arial",sans-serif\">\u003Cspan style=\"color:black\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n","\u003Cp>\u003Cem>\u003Cstrong>Guilhem, warum haben Sie eine attraktive Position in einem Grosskonzern verlassen, um Healios zu gründen?\u003C\u002Fstrong>\u003C\u002Fem>\u003Cbr>\n\u003Cbr>\nIm heutigen Zeitalter der digitalen Transformation bieten sich im Gesundheitswesen riesige Chancen. Es werden noch mehr belastbare Real-World-Daten benötigt, um den Behandlungserfolg zu messen, und wir brauchen genauere Diagnostika, mit denen sich die Behandlungen personalisieren lassen. Hier kommt Healios ins Spiel: Wir nutzen Sensordaten von Wearables und Smartphones, um das Fortschreiten neurologischer Krankheiten wie der Multiplen Sklerose (MS) zu messen. \u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan lang=\"EN-GB\">\u003Cspan>\u003Cspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>",{"__typename":248,"id":265,"ctaLink":208,"pgSharedText":266,"pgSharedTitle":208,"pgSharedCtaLink":208},"5668",{"value":267,"processed":268,"format":253},"\u003Cp>\u003Cem>\u003Cstrong>Wozu dient das?\u003C\u002Fstrong>\u003C\u002Fem>\u003Cbr \u002F>\r\n\u003Cbr \u002F>\r\nDank unserer Lösung können Fachärzte den Krankheitsfortschritt früher und genauer bestimmen als mit den heutigen Methoden. So lässt sich die Behandlung anpassen, um Einschränkungen zu vermindern und das weitere Fortschreiten der Krankheit zu verlangsamen, wovon Patienten, Ärzte und die Krankenkassen profitieren. Mit derselben Lösung tragen wir auch zur klinischen Forschung bei, einem Bereich, in dem die Einführung digitaler Lösungen im Zuge von Covid-19 exponentiell zugenommen hat.\u003C\u002Fp>\r\n","\u003Cp>\u003Cem>\u003Cstrong>Wozu dient das?\u003C\u002Fstrong>\u003C\u002Fem>\u003Cbr>\n\u003Cbr>\nDank unserer Lösung können Fachärzte den Krankheitsfortschritt früher und genauer bestimmen als mit den heutigen Methoden. So lässt sich die Behandlung anpassen, um Einschränkungen zu vermindern und das weitere Fortschreiten der Krankheit zu verlangsamen, wovon Patienten, Ärzte und die Krankenkassen profitieren. Mit derselben Lösung tragen wir auch zur klinischen Forschung bei, einem Bereich, in dem die Einführung digitaler Lösungen im Zuge von Covid-19 exponentiell zugenommen hat.\u003C\u002Fp>",{"__typename":270,"id":271,"caption":208,"imageRight":208,"pgSharedTitle":208,"pgSharedCtaLink":208,"textMedia":272,"pgSharedText":292},"ParagraphPgTextMedia","5669",{"id":273,"sharedMediaLegend":208,"mediaImage":274,"name":291},"2543",{"url":275,"width":276,"height":277,"alt":278,"title":208,"size":279,"mime":280,"variations":208,"textMediaVariations":281},"https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fimages\u002Fportrait_guilhem-dupont.jpg",388,342,"portrait of Guilhem Dupont, CEO Healios",19264,"image\u002Fjpeg",[282,285,286,287,290],{"name":283,"url":284,"width":276,"height":277},"FIXED_WIDTH_SMALL","https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Ffixed_width_small\u002Fpublic\u002Fimages\u002Fportrait_guilhem-dupont.jpg.webp?itok=Y0F9oqU4",{"name":283,"url":284,"width":276,"height":277},{"name":283,"url":284,"width":276,"height":277},{"name":288,"url":289,"width":276,"height":277},"FIXED_WIDTH_MEDIUM","https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Ffixed_width_medium\u002Fpublic\u002Fimages\u002Fportrait_guilhem-dupont.jpg.webp?itok=s5k5JwL3",{"name":288,"url":289,"width":276,"height":277},"portrait_guilhem-dupont.jpg",{"value":293,"processed":294,"format":253},"\u003Cp>\u003Cstrong>Guilhem Dupont\u003C\u002Fstrong>\u003Cbr \u002F>\r\n\u003Cbr \u002F>\r\n\u003Ca href=\"https:\u002F\u002Fwww.linkedin.com\u002Fin\u002Fguilhem-dupont-8271591\u002F\" target=\"_blank\">Guilhem Dupont\u003C\u002Fa> engagiert sich leidenschaftlich für die Unterstützung von Patienten und Pflegekräften, die von einer chronischen Erkrankung betroffen sind. Guilhem arbeitete 12 Jahre lang in globalen Führungspositionen bei Johnson & Johnson und Roche.\u003C\u002Fp>\r\n","\u003Cp>\u003Cstrong>Guilhem Dupont\u003C\u002Fstrong>\u003Cbr>\n\u003Cbr>\n\u003Ca href=\"https:\u002F\u002Fwww.linkedin.com\u002Fin\u002Fguilhem-dupont-8271591\u002F\" target=\"_blank\">Guilhem Dupont\u003C\u002Fa> engagiert sich leidenschaftlich für die Unterstützung von Patienten und Pflegekräften, die von einer chronischen Erkrankung betroffen sind. Guilhem arbeitete 12 Jahre lang in globalen Führungspositionen bei Johnson & Johnson und Roche.\u003C\u002Fp>",{"__typename":248,"id":296,"ctaLink":208,"pgSharedText":297,"pgSharedTitle":208,"pgSharedCtaLink":208},"5670",{"value":298,"processed":299,"format":253},"\u003Cp>\u003Cem>\u003Cstrong>Welche Partner unterstützen Sie dabei?\u003C\u002Fstrong>\u003C\u002Fem>\u003Cbr \u002F>\r\n\u003Cbr \u002F>\r\nWir haben das Glück, Teil einer weltweit führenden Gruppe gut aufeinander abgestimmter Partner über die gesamte Wertschöpfungskette hinweg zu sein. Das international renommierte \u003Ca href=\"https:\u002F\u002Fdkf.unibas.ch\u002Fde\u002Frc2nb\u002F\" target=\"_blank\">RC2NB\u003C\u002Fa> (Research Center for Clinical Neuroimmunology and Neuroscience Basel) unter der Leitung von Prof. Ludwig Kappos ist führend im Bereich der MS-Therapien und der umfassenden Krankheitsbeurteilung. Es widmet sich engagiert der Forschung zu digitalen Biomarkern für die MS und hat Kooperationsverträge mit \u003Ca href=\"https:\u002F\u002Fwww.roche.com\u002Fde.htm\" target=\"_blank\">Roche\u003C\u002Fa> und \u003Ca href=\"https:\u002F\u002Fwww.novartis.ch\u002Fde\" target=\"_blank\">Novartis\u003C\u002Fa> unterzeichnet, um die Forschung und die Umsetzung der Ergebnisse weiter zu beschleunigen. Zühlke Ventures war nicht nur als Ankeraktionär an der Seed-Finanzierung beteiligt, sondern unterstützt auch aktiv unsere Skalierungsbemühungen.\u003Cspan style=\"font-size:11pt\">\u003Cspan style=\"vertical-align:middle\">\u003Cspan style=\"font-family:Calibri,sans-serif\">\u003Cspan style=\"font-size:12.0pt\">\u003Cspan style=\"font-family:"Arial",sans-serif\">\u003Cspan style=\"color:black\"> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\r\n","\u003Cp>\u003Cem>\u003Cstrong>Welche Partner unterstützen Sie dabei?\u003C\u002Fstrong>\u003C\u002Fem>\u003Cbr>\n\u003Cbr>\nWir haben das Glück, Teil einer weltweit führenden Gruppe gut aufeinander abgestimmter Partner über die gesamte Wertschöpfungskette hinweg zu sein. Das international renommierte \u003Ca href=\"https:\u002F\u002Fdkf.unibas.ch\u002Fde\u002Frc2nb\u002F\" target=\"_blank\">RC2NB\u003C\u002Fa> (Research Center for Clinical Neuroimmunology and Neuroscience Basel) unter der Leitung von Prof. Ludwig Kappos ist führend im Bereich der MS-Therapien und der umfassenden Krankheitsbeurteilung. Es widmet sich engagiert der Forschung zu digitalen Biomarkern für die MS und hat Kooperationsverträge mit \u003Ca href=\"https:\u002F\u002Fwww.roche.com\u002Fde.htm\" target=\"_blank\">Roche\u003C\u002Fa> und \u003Ca href=\"https:\u002F\u002Fwww.novartis.ch\u002Fde\" target=\"_blank\">Novartis\u003C\u002Fa> unterzeichnet, um die Forschung und die Umsetzung der Ergebnisse weiter zu beschleunigen. Zühlke Ventures war nicht nur als Ankeraktionär an der Seed-Finanzierung beteiligt, sondern unterstützt auch aktiv unsere Skalierungsbemühungen.\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>",{"__typename":248,"id":301,"ctaLink":208,"pgSharedText":302,"pgSharedTitle":208,"pgSharedCtaLink":208},"5671",{"value":303,"processed":304,"format":253},"\u003Cp>\u003Cem>\u003Cstrong>Wo sehen Sie die grössten Herausforderungen?\u003C\u002Fstrong>\u003C\u002Fem>\u003Cbr \u002F>\r\n\u003Cbr \u002F>\r\nWir haben schon in der Vergangenheit erfolgreich digitale Gesundheitsprodukte entwickelt und ein gut strukturiertes Unternehmen aufgebaut. Die grösste Herausforderung besteht darin, das schnelle Wachstum in den Griff zu bekommen, das angesichts der hohen Nachfrage nötig ist.\u003C\u002Fp>\r\n","\u003Cp>\u003Cem>\u003Cstrong>Wo sehen Sie die grössten Herausforderungen?\u003C\u002Fstrong>\u003C\u002Fem>\u003Cbr>\n\u003Cbr>\nWir haben schon in der Vergangenheit erfolgreich digitale Gesundheitsprodukte entwickelt und ein gut strukturiertes Unternehmen aufgebaut. Die grösste Herausforderung besteht darin, das schnelle Wachstum in den Griff zu bekommen, das angesichts der hohen Nachfrage nötig ist.\u003C\u002Fp>",{"__typename":248,"id":306,"ctaLink":208,"pgSharedText":307,"pgSharedTitle":208,"pgSharedCtaLink":208},"5672",{"value":308,"processed":309,"format":253},"\u003Cp>\u003Cstrong>\u003Cem>Welche Meilensteine möchte Healios als Nächstes erreichen?\u003C\u002Fem>\u003C\u002Fstrong>\u003Cbr \u002F>\r\n\u003Cbr \u002F>\r\nWir sind überzeugt, noch weitere Partner einbinden zu können, und freuen uns darauf, das Leben von Menschen mit neurologischen Krankheiten langfristig und nachhaltig zu verbessern.\u003C\u002Fp>\r\n","\u003Cp>\u003Cstrong>\u003Cem>Welche Meilensteine möchte Healios als Nächstes erreichen?\u003C\u002Fem>\u003C\u002Fstrong>\u003Cbr>\n\u003Cbr>\nWir sind überzeugt, noch weitere Partner einbinden zu können, und freuen uns darauf, das Leben von Menschen mit neurologischen Krankheiten langfristig und nachhaltig zu verbessern.\u003C\u002Fp>",{"__typename":311,"id":312,"title":208,"pgContactRefContacts":313,"showEmail":208,"showPhone":208},"ParagraphPgContact","5673",[314],{"contactName":315,"contactProfession":316,"contactDesc":317,"contactLinkedinUrl":319,"sharedEmail":322,"sharedPhone":323,"sharedRefMedia":324},"Patrick Griss ","CEO Ventures & Partner",{"value":318},"",{"title":318,"url":320,"internal":321},"http:\u002F\u002Flinkedin.com\u002Fin\u002Fpatrick-griss-5b44a07",false,"patrick.griss@zuehlke.com","+41 43 216 6609",{"id":325,"sharedMediaLegend":208,"mediaImage":326,"name":342},"172061",{"url":327,"width":328,"height":328,"alt":329,"title":208,"size":330,"mime":280,"variations":208,"personVariations":331},"https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fimages\u002FPatrick-Griss-1000x1000px.jpg",1000,"Patrick Griss, Zühlke",244558,[332,336,337,340,341],{"name":333,"url":334,"width":335,"height":335},"FOCAL_POINT11_SMALL","https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Ffocal_point_1_1_small\u002Fpublic\u002Fimages\u002FPatrick-Griss-1000x1000px.jpg.webp?itok=7-4ZdwfA",800,{"name":333,"url":334,"width":335,"height":335},{"name":338,"url":339,"width":328,"height":328},"FOCAL_POINT11_MEDIUM","https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Ffocal_point_1_1_medium\u002Fpublic\u002Fimages\u002FPatrick-Griss-1000x1000px.jpg.webp?itok=-RC0Pygr",{"name":338,"url":339,"width":328,"height":328},{"name":338,"url":339,"width":328,"height":328},"Patrick-Griss-1000x1000px.jpg",[344,347],{"id":345,"name":346},"13","MedTech",{"id":348,"name":349},"12","Pharma",[351],{"id":352,"name":353},"21","Softwareentwicklung",{"timestamp":355},1617192000,[357],{"status":7,"contactName":315,"contactProfession":316,"contactLinkedinUrl":358,"sharedEmail":322,"sharedRefMedia":359},{"title":318,"url":320,"internal":321},{"id":325,"sharedMediaLegend":208,"mediaImage":360,"name":342},{"url":327,"width":328,"height":328,"alt":329,"title":208,"size":330,"mime":280,"variations":208,"authorVariations":361},[362,363,364,365,366],{"name":333,"url":334,"width":335,"height":335},{"name":333,"url":334,"width":335,"height":335},{"name":333,"url":334,"width":335,"height":335},{"name":333,"url":334,"width":335,"height":335},{"name":333,"url":334,"width":335,"height":335},[368,410,441,474],{"id":369,"path":370,"sharedTeaserTitle":371,"sharedTeaserRefMedia":372,"sharedTaxrefIndustries":392,"sharedTaxrefExpertises":396},"27064","\u002Fde\u002Finsights\u002Fwie-sich-die-produktentwicklung-veraendert-wenn-produkte-zu-cyber-physikalischen-systemen","Wie cyber-physikalische Systeme die Produktentwicklung verändern",{"id":373,"sharedMediaLegend":208,"mediaImage":374,"name":391},"173232",{"url":375,"width":376,"height":377,"alt":378,"title":208,"size":379,"mime":280,"variations":208,"relatedContentVariations":380},"https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fimages\u002FHow%20development%20changes%20when%20products%20become%20cyber-physical%20systems.jpeg",5600,3738,"Two men with tablet talking in factory shop floor",4662335,[381,384,385,389,390],{"name":229,"url":382,"width":335,"height":383},"https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Ffocal_point_3_2_small\u002Fpublic\u002Fimages\u002FHow%20development%20changes%20when%20products%20become%20cyber-physical%20systems.jpeg.webp?itok=kyI5fNKF",533,{"name":229,"url":382,"width":335,"height":383},{"name":386,"url":387,"width":388,"height":335},"FOCAL_POINT32_MEDIUM","https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Ffocal_point_3_2_medium\u002Fpublic\u002Fimages\u002FHow%20development%20changes%20when%20products%20become%20cyber-physical%20systems.jpeg.webp?itok=whBTsZR-",1200,{"name":386,"url":387,"width":388,"height":335},{"name":386,"url":387,"width":388,"height":335},"How development changes when products become cyber-physical systems.jpeg",[393],{"id":394,"name":395},"10","Industrie",[397,400,403,406,409],{"id":398,"name":399},"110","KI",{"id":401,"name":402},"19","Digitale Strategien",{"id":404,"name":405},"887","Business Transformation",{"id":407,"name":408},"20","Hardwareentwicklung",{"id":352,"name":353},{"id":411,"path":412,"sharedTeaserTitle":413,"sharedTeaserRefMedia":414,"sharedTaxrefIndustries":432,"sharedTaxrefExpertises":436},"1889","\u002Fde\u002Finsights\u002Fdigitaler-individueller-schneller-mit-low-code-plattformen","Digitaler, Individueller, Schneller mit Low-Code-Plattformen",{"id":415,"sharedMediaLegend":208,"mediaImage":416,"name":431},"1533",{"url":417,"width":418,"height":419,"alt":420,"title":208,"size":421,"mime":280,"variations":208,"relatedContentVariations":422},"https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fimages\u002Flow-code-zuehlke_0.jpg",1024,768,"Low Code Zühlke",581212,[423,425,426,429,430],{"name":229,"url":424,"width":335,"height":383},"https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Ffocal_point_3_2_small\u002Fpublic\u002Fimages\u002Flow-code-zuehlke_0.jpg.webp?itok=_RPQUa4t",{"name":229,"url":424,"width":335,"height":383},{"name":386,"url":427,"width":418,"height":428},"https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Ffocal_point_3_2_medium\u002Fpublic\u002Fimages\u002Flow-code-zuehlke_0.jpg.webp?itok=jrz0fvPN",683,{"name":386,"url":427,"width":418,"height":428},{"name":386,"url":427,"width":418,"height":428},"low-code-zuehlke.jpg",[433],{"id":434,"name":435},"11","Versicherungen",[437,438],{"id":352,"name":353},{"id":439,"name":440},"897","Low Code",{"id":442,"path":443,"sharedTeaserTitle":444,"sharedTeaserRefMedia":445,"sharedTaxrefIndustries":462,"sharedTaxrefExpertises":466},"26969","\u002Fde\u002Finsights\u002Fmodernisierung-der-kernbankensysteme-mammutaufgabe-fuer-den-cio","Modernisierung von Legacy-Banking-Systemen: CIO-Aufgabe",{"id":446,"sharedMediaLegend":208,"mediaImage":447,"name":461},"172976",{"url":448,"width":449,"height":450,"alt":451,"title":208,"size":452,"mime":226,"variations":208,"relatedContentVariations":453},"https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fimages\u002FBanking_Programme_Web_Imagery_Header_Blog2.png",2880,1620,"Abstract visual of data transforming into modular digital architecture, representing AI-driven legacy system modernisation.",8482270,[454,456,457,459,460],{"name":229,"url":455,"width":335,"height":383},"https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Ffocal_point_3_2_small\u002Fpublic\u002Fimages\u002FBanking_Programme_Web_Imagery_Header_Blog2.png.webp?itok=6f7XyxGN",{"name":229,"url":455,"width":335,"height":383},{"name":386,"url":458,"width":388,"height":335},"https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Ffocal_point_3_2_medium\u002Fpublic\u002Fimages\u002FBanking_Programme_Web_Imagery_Header_Blog2.png.webp?itok=xbyRV2lX",{"name":386,"url":458,"width":388,"height":335},{"name":386,"url":458,"width":388,"height":335},"Banking_Programme_Web_Imagery_Header_Blog2.png",[463],{"id":464,"name":465},"7","Banken & Finanzdienstleister",[467,468,471,472,473],{"id":398,"name":399},{"id":469,"name":470},"874","Generative KI",{"id":401,"name":402},{"id":404,"name":405},{"id":352,"name":353},{"id":475,"path":476,"sharedTeaserTitle":477,"sharedTeaserRefMedia":478,"sharedTaxrefIndustries":495,"sharedTaxrefExpertises":497},"26103","\u002Fde\u002Finsights\u002Finsurance-wie-und-wo-low-code-angewendet-werden-kann","Wie man Low-Code-Technologien in der Versicherungsbranche einsetzt",{"id":479,"sharedMediaLegend":208,"mediaImage":480,"name":494},"170636",{"url":481,"width":482,"height":483,"alt":484,"title":208,"size":485,"mime":280,"variations":208,"relatedContentVariations":486},"https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fimages\u002Flow-code-in-insurance.jpg",1280,910,"\"\"",149716,[487,489,490,492,493],{"name":229,"url":488,"width":335,"height":383},"https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Ffocal_point_3_2_small\u002Fpublic\u002Fimages\u002Flow-code-in-insurance.jpg.webp?itok=aQ9cWTjC",{"name":229,"url":488,"width":335,"height":383},{"name":386,"url":491,"width":388,"height":335},"https:\u002F\u002Fcms.zuehlke.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Ffocal_point_3_2_medium\u002Fpublic\u002Fimages\u002Flow-code-in-insurance.jpg.webp?itok=yIAGbZf0",{"name":386,"url":491,"width":388,"height":335},{"name":386,"url":491,"width":388,"height":335},"low-code-in-insurance.jpg",[496],{"id":434,"name":435},[498,501,502],{"id":499,"name":500},"891","Neue Technologien",{"id":352,"name":353},{"id":439,"name":440}]